



May 2006

**HELINN NEWS**



## ANOTHER PROMISING RESULT FOR HELSINN AT THE 5<sup>th</sup> EUROPEAN ONCOLOGY NURSING SOCIETY SPRING CONVENTION (EONS)

Innsbruck, 20-22 April 2006

The 5<sup>th</sup> EONS spring convention hosted in Innsbruck, Austria, from 20-22<sup>nd</sup> April last, was certainly very positive for both Aloxi<sup>®</sup> and Gelclair<sup>®</sup>.



Helsinn's booth was one of the most visited in the exhibition area, attracting European as well as South African and US nurses. Confirmation of the success Aloxi<sup>®</sup> and Gelclair<sup>®</sup> are enjoying worldwide came from the strong interest nurses showed in both products and from the considerable request for recent

publications and literature and information on the products' characteristics and key attributes as well as their availability in various countries.



May 2006

## HELINN **N**NEWS

The visitors to Helsinn's booth also had the possibility of navigating in Helsinn's Aloxi®'s website, gathering the latest scientific and marketing news, and of watching the video of engaging interviews to our distinguished Opinion Leaders.

Throughout the event, Helsinn's staff carried out a very interesting survey among the booth visitors on the clinical practice in CINV.

There was a solid participation in Helsinn's Satellite Symposium held on 21<sup>st</sup> April, "*Do your patients still suffer chemotherapy induced nausea and vomiting? A new option for optimal control*", which saw two presentations:

- *Palonosetron prevents CINV with a single dose - the evidence*  
*Alan Stewart, MD, Christie Hospital NHS Trust, Manchester, UK*
- *The benefits of successful prevention of CINV for the patient and the nurse*  
*Rebecca Clark-Snow, RN, BSN, OCN, University of Kansas Hospital Cancer Center, Kansas City (KS), USA*

At the close of the Symposium, Helsinn ran a fascinating interactive activity which required the audience's contribution. A film was broadcast and the participants were asked to pinpoint and evidence the errors seen during the video by means of an electronic keypad.

At the end of the activity, the errors were revealed and commented by the speakers. This survey was very much appreciated by the audience.

A poster on Aloxi® was also presented,

*"Palonosetron , a 5-HT<sub>3</sub> Receptor Antagonist (RA), conveniently offers prevention of CINV", by Linda Denman (Christie Hospital, Manchester, UK).*



May 2006

## HELINN **N** EWS

Although there was no official poster presentation session at this convention, the poster attracted the interest of many visitors, who requested a handout of the poster.

Another significant message on Aloxi<sup>®</sup> was conveyed during the scientific programme where it was clearly stated that “as for granisetron, palonosetron DOES NOT demonstrate problems regarding QTc prolongation”.

A particular acknowledgement goes to Helsinn’s partners who contributed with great enthusiasm and strong commitment to the success that Aloxi<sup>®</sup> and Gelclair<sup>®</sup> met in this convention.

All of Helsinn’s partners, their invited guests and visitors expressed a positive feedback on all of the activities organised by Helsinn, which reinforces the strong general interest shown in Aloxi<sup>®</sup> and Gelclair<sup>®</sup>.